Policy & Regulation
NRx Pharmaceuticals' intravenous ZYESAMI (aviptadil) receives Georgian Emergency Use Authorisation
28 July 2021 -

NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, announced on Tuesday that it has received an Emergency Use Authorisation from the Nation of Georgia's prime minister and minister of health for intravenous ZYESAMI (aviptadil) to treat Critical COVID-19.

The product received approval after Georgian doctors saw significant, daily increases in COVID-19 cases, hospitalised patients, specifically patients in hospital intensive care units.

Dr Javier Perez-Fernandez, a lead investigator in the Phase 2b/3 clinical trial of intravenous ZYESAMI (aviptadil), and critical care pulmonologist in Miami, Florida, is leading the team of physicians traveling to Georgia to train fellow doctors there in administering ZYESAMI and the effects of the medicine.

The first doses of the product are to arrive in the Nation of Georgia within 24 hours, and discussions are underway with the Ministry of Health to offer Georgians suffering with Critical COVID-19 access to the product.